Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
NCT07594119 · FOCUS 2 Phase 3Recruiting
- Lead sponsor
- Rapport Therapeutics Inc. (Industry)
- Enrollment
- 312 (estimated)
- Start date
- 1 Sep 2026
- Primary completion
- Jul 2029 (estimated)
- Study completion
- 1 Sep 2029
- Last update posted
- 15 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 3
Interventions
- RAP-219 Drug
- Placebo Other
Conditions and primary outcome
- Focal Seizure
- Epilepsy
- Focal Epilepsy
Primary outcome
Median Percent Change in Seizure Frequency (End of double-blind treatment period (end of week 14) vs Baseline)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07594119.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07594119 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.